Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

The Dividend Harvesting Portfolio hit new all-time highs, delivering a 29.44% return. Learn more about the portfolio and why ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...